NASDAQ:ILMN - Illumina Stock Price, Forecast & News

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings results on Thursday, October, 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.40 by $0.53. The life sciences company earned $907 million during the quarter, compared to analyst estimates of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. Illumina's quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.52 EPS. View Illumina's Earnings History.

Illumina is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Illumina.

Illumina will be holding an earnings conference call on Wednesday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Illumina issued an update on its fourth quarter 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $950-950 million, compared to the consensus revenue estimate of $939.29 million.

16 Wall Street analysts have issued twelve-month price targets for Illumina's stock. Their forecasts range from $280.00 to $385.00. On average, they expect Illumina's share price to reach $339.73 in the next year. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Price Targets for Illumina.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.

Media coverage about ILMN stock has trended negative on Saturday, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Illumina earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media stories about the life sciences company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Illumina.

Illumina saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,610,000 shares, an increase of 8.4% from the December 15th total of 3,330,000 shares. Based on an average daily volume of 868,000 shares, the days-to-cover ratio is presently 4.2 days. Currently, 2.5% of the company's shares are short sold. View Illumina's Current Options Chain.

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Visa (V), Walt Disney (DIS), Baidu (BIDU), Adobe (ADBE), Tesla (TSLA), Micron Technology (MU) and Paypal (PYPL).

Illumina's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.06%), Gateway Investment Advisers LLC (0.05%), Copper Rock Capital Partners LLC (0.03%), Assenagon Asset Management S.A. (0.03%), Capital Investment Services of America Inc. (0.03%) and Hemenway Trust Co LLC (0.03%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View Institutional Ownership Trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Spence Asset Management, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Gateway Investment Advisers LLC, Anderson Hoagland & Co., State of Alaska Department of Revenue, Nisa Investment Advisors LLC and Arthur M. Cohen & Associates LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View Insider Buying and Selling for Illumina.

ILMN stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Capital Investment Services of America Inc., Vigilant Capital Management LLC, Alpine Global Management LLC, Farmers Trust Co., Baxter Bros Inc., West Oak Capital LLC and DNB Asset Management AS. View Insider Buying and Selling for Illumina.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ILMN stock can currently be purchased for approximately $324.72.

Illumina has a market capitalization of $47.73 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe.View Additional Information About Illumina.

The official website for Illumina is http://www.illumina.com/.

Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]